相似文献
1
Anti-interleukin-17A for pityriasis rubra pilaris: catching the psoriasis biologic wave.
Br J Dermatol. 2022 Nov;187(5):633-634. doi: 10.1111/bjd.21813. Epub 2022 Aug 22.
2
Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
Br J Dermatol. 2022 Nov;187(5):650-658. doi: 10.1111/bjd.21708. Epub 2022 Jul 15.
3
Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.
JAMA Dermatol. 2020 Jun 1;156(6):668-675. doi: 10.1001/jamadermatol.2020.0932.
4
Biologic treatment options for pityriasis rubra pilaris: An evidence-based systematic review.
J Am Acad Dermatol. 2023 Dec;89(6):1306-1308. doi: 10.1016/j.jaad.2023.08.057. Epub 2023 Aug 26.
5
Methotrexate treatment in a case of juvenile pityriasis rubra pilaris.
Pediatr Dermatol. 2018 Jan;35(1):e62-e63. doi: 10.1111/pde.13326. Epub 2017 Oct 17.
6
[Pityriasis rubra pilaris : Successful treatment with ixekizumab].
Hautarzt. 2020 Aug;71(8):624-626. doi: 10.1007/s00105-020-04575-6.
7
Rapid response of pityriasis rubra pilaris with psoriasis overlap to secukinumab.
Br J Dermatol. 2019 Dec;181(6):1331-1332. doi: 10.1111/bjd.18263. Epub 2019 Aug 27.
8
Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris.
Cutis. 2018 May;101(5):367-369.
9
Topical treatment of pityriasis rubra pilaris with calcipotriol.
Br J Dermatol. 1994 May;130(5):675-8. doi: 10.1111/j.1365-2133.1994.tb13121.x.
10
Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient.
J Drugs Dermatol. 2007 Mar;6(3):337-9.
本文引用的文献
1
Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
Br J Dermatol. 2022 Nov;187(5):650-658. doi: 10.1111/bjd.21708. Epub 2022 Jul 15.
2
Beyond plaque psoriasis - pathogenesis and treatment of other psoriasis phenotypes.
Curr Opin Rheumatol. 2022 Jul 1;34(4):225-234. doi: 10.1097/BOR.0000000000000882. Epub 2022 Jun 9.
3
Response to: 'Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab'.
Br J Dermatol. 2021 Jul;185(1):235-236. doi: 10.1111/bjd.20061. Epub 2021 Apr 18.
4
Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.
JAMA Dermatol. 2020 Jun 1;156(6):668-675. doi: 10.1001/jamadermatol.2020.0932.
5
Blueprint for mechanistic, data-rich early phase clinical pharmacology studies in dermatology.
Br J Clin Pharmacol. 2020 Jun;86(6):1011-1014. doi: 10.1111/bcp.14293. Epub 2020 Apr 6.
6
Learning From Success and Failure: Biologics for Non-approved Skin Diseases.
Front Immunol. 2019 Aug 8;10:1918. doi: 10.3389/fimmu.2019.01918. eCollection 2019.
7
Secukinumab in pityriasis rubra pilaris: A case series demonstrating variable response and the need for minimal clinical datasets.
JAAD Case Rep. 2018 May 7;4(5):500-505. doi: 10.1016/j.jdcr.2018.02.007. eCollection 2018 Jun.
8
A Review on Pityriasis Rubra Pilaris.
Am J Clin Dermatol. 2018 Jun;19(3):377-390. doi: 10.1007/s40257-017-0338-1.
9
Pityriasis rubra pilaris: algorithms for diagnosis and treatment.
J Eur Acad Dermatol Venereol. 2018 Jun;32(6):889-898. doi: 10.1111/jdv.14761. Epub 2018 Jan 17.
10
Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris.
JAMA Dermatol. 2017 Apr 1;153(4):304-308. doi: 10.1001/jamadermatol.2016.5384.
Zotero 插件